The mass rollout of AI-powered genomic health prediction (AIGHP) could pose significant risks concerning privacy and discrimination, according to a report by the Ada Lovelace Institute and the Nuffield Council on Bioethics (NCOB).
AIGHP involves AI-driven techniques that utilize genomic data to make predictions about individuals’ future health and responses to medications.
The report, ‘Predicting: The future of healthcare?’, released on September 11, 2024, examines the potential benefits and risks of integrating AIGHP into the UK healthcare system.
It raises concerns about scientific uncertainty, privacy risks, genetic discrimination, NHS technology adoption challenges, and public perceptions of AIGHP.
The Ada Lovelace Institute and NCOB recommend a cautious approach to AIGHP implementation within the NHS and suggest targeted usage based on specific needs.
Policy suggestions include enhanced data protection guidelines and a revamped patient consent model for sharing genomic data.
While acknowledging the benefits of genomic health prediction, researchers urge careful consideration, emphasizing the need to address privacy and discrimination issues and build public trust.
They stress the importance of targeted AIGHP deployments within a robust regulatory framework rather than a widespread public health tool.
The UK government has outlined strategies, such as ‘Genome UK: Future of healthcare’ in 2020, that highlight AIGHP’s potential to enhance preventative and personalized healthcare within the NHS.
It is essential to engage the public fully and embed ethical considerations to ensure the responsible and trusted use of AIGHP in the healthcare system.
Building on the DNA.I report from August 2023, which explored ethical and legal implications of AI and genomics integration, this new report offers valuable insights.
Digital Health News sought comments from NHS England and the Department of Health and Social Care but had not received a response at the time of publication.
